TY - JOUR T1 - Spanish Evidence-Based Guidelines on the Treatment of Psoriasis With Biologic Agents, 2013. Part 1: On Efficacy and Choice of Treatment JO - Actas Dermo-Sifiliográficas T2 - AU - Puig,L. AU - Carrascosa,J.M. AU - Carretero,G. AU - de la Cueva,P. AU - Lafuente-Urrez,R.F. AU - Belinchón,I. AU - Sánchez-Regaña,M. AU - García-Bustínduy,M. AU - Ribera,M. AU - Alsina,M. AU - Ferrándiz,C. AU - Fonseca,E. AU - García-Patos,V. AU - Herrera,E. AU - López-Estebaranz,J.L. AU - Marrón,S.E. AU - Moreno,J.C. AU - Notario,J. AU - Rivera,R. AU - Rodriguez-Cerdeira,C. AU - Romero,A. AU - Ruiz-Villaverde,R. AU - Taberner,R. AU - Vidal,D. SN - 15782190 M3 - 10.1016/j.adengl.2013.04.013 DO - 10.1016/j.adengl.2013.04.013 UR - https://www.actasdermo.org/es-spanish-evidence-based-guidelines-on-treatment-articulo-S1578219013001789 AB - Biologic therapy is a well-established strategy for managing moderate and severe psoriasis. Nevertheless, the high cost of such therapy, the relatively short span of clinical experience with biologics, and the abundance of literature now available on these agents have made evidence-based and consensus-based clinical guidelines necessary. The ideal goal of psoriasis treatment is to achieve complete or nearly complete clearing of lesions and to maintain it over time. Failing that ideal, the goal would be to reduce involvement to localized lesions that can be controlled with topical therapy. Although current evidence allows us to directly or indirectly compare the efficacy or risk of primary or secondary failure of available biologics based on objective outcomes, clinical trial findings cannot be directly translated to routine practice. As a result, the prescribing physician must tailor the treatment regimen to the individual patient. This update of the clinical practice guidelines issued by the Spanish Academy of Dermatology and Venereology (AEDV) on biologic therapy for psoriasis incorporates information from the most recent publications on this topic. ER -